A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine followed by an open follow-up evaluation to assess consistency

Trial Profile

A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine followed by an open follow-up evaluation to assess consistency

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2011

At a glance

  • Drugs Almotriptan (Primary)
  • Indications Menstrual migraine
  • Focus Therapeutic Use
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 13 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top